doi:10.1210/jc.2014-3016
15 As a result, public companies are already seeing a growing number of questions from investors and media around GLP-1RAs and the impact they may have on their business
Novo Nordisks blockbuster molecule, semaglutide, was launched for Type 2 diabetes (T2D) in 2018 as Ozempic
Fleming R, Estey E, Kantarjian H, OBrien S, Keating M, Kornblau S, Freireich E, Andreeff M , Cortez J, Vassilaki M, Turan A, Risser J, Luna M, Anaissie E
While mild symptoms may improve naturally over time, persistent burning, fever, discomfort, or pain when passing urine should always be assessed carefully because some early warning signs may seem surprisingly easy to dismiss at first